Insider Transactions in Q4 2021 at Merck & Co., Inc. (MRK)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 09
2021
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
663,881
-27.76%
|
$54,438,242
$82.73 P/Share
|
|
Nov 09
2021
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
663,881
+34.68%
|
-
|
|
Nov 04
2021
|
Caroline Litchfield EVP & CFO |
SELL
Open market or private sale
|
Direct |
18,335
-43.19%
|
$1,668,485
$91.0 P/Share
|
|
Nov 04
2021
|
Caroline Litchfield EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,683
+34.83%
|
-
|
|
Nov 04
2021
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Open market or private sale
|
Direct |
29,782
-20.3%
|
$2,680,380
$90.4 P/Share
|
|
Nov 04
2021
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
29,782
+16.87%
|
-
|
|
Nov 03
2021
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Open market or private sale
|
Direct |
25,000
-41.12%
|
$2,200,000
$88.45 P/Share
|
|
Nov 03
2021
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+29.14%
|
-
|
|
Nov 01
2021
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Open market or private sale
|
Direct |
96,270
-71.08%
|
$8,375,490
$87.91 P/Share
|
|
Nov 01
2021
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
96,270
+18.96%
|
-
|
|
Nov 01
2021
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Open market or private sale
|
Direct |
39,762
-29.05%
|
$3,459,294
$87.87 P/Share
|
|
Nov 01
2021
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
39,762
+13.6%
|
-
|
|
Oct 30
2021
|
Steven Mizell EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,323
-8.33%
|
$204,424
$88.05 P/Share
|
|
Oct 30
2021
|
Steven Mizell EVP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,715
+14.46%
|
$414,920
$88.05 P/Share
|
|
Oct 30
2021
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Payment of exercise price or tax liability
|
Direct |
1,162
-1.18%
|
$102,256
$88.05 P/Share
|
|
Oct 30
2021
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
2,358
+2.34%
|
$207,504
$88.05 P/Share
|
|
Oct 29
2021
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Open market or private sale
|
Direct |
135,405
-53.66%
|
$11,780,235
$87.56 P/Share
|
|
Oct 29
2021
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
135,405
+23.79%
|
-
|
|
Oct 29
2021
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
SELL
Open market or private sale
|
Direct |
24,619
-20.91%
|
$2,141,853
$87.32 P/Share
|
|
Oct 29
2021
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Exercise of conversion of derivative security
|
Direct |
24,619
+17.29%
|
-
|